Cidel Asset Management Inc. Acquires 109,239 Shares of Haleon PLC Sponsored ADR $HLN

Cidel Asset Management Inc. boosted its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 30.0% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 473,692 shares of the company’s stock after purchasing an additional 109,239 shares during the quarter. Cidel Asset Management Inc.’s holdings in Haleon were worth $4,742,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. First Eagle Investment Management LLC boosted its stake in shares of Haleon by 9.8% in the third quarter. First Eagle Investment Management LLC now owns 3,056,951 shares of the company’s stock valued at $27,421,000 after buying an additional 273,044 shares during the period. Third View Private Wealth LLC bought a new position in Haleon during the 4th quarter worth $3,461,000. Optiver Holding B.V. bought a new position in Haleon during the 3rd quarter worth $45,593,000. Cantor Fitzgerald L. P. acquired a new position in Haleon in the 3rd quarter valued at $1,409,000. Finally, Scharf Investments LLC raised its holdings in Haleon by 17.4% in the 4th quarter. Scharf Investments LLC now owns 1,095,734 shares of the company’s stock valued at $11,078,000 after acquiring an additional 162,406 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Stock Up 2.3%

NYSE HLN opened at $8.97 on Wednesday. The business has a fifty day moving average price of $9.21 and a two-hundred day moving average price of $9.87. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. Haleon PLC Sponsored ADR has a fifty-two week low of $8.65 and a fifty-two week high of $11.28. The stock has a market capitalization of $39.68 billion, a PE ratio of 23.00, a PEG ratio of 2.02 and a beta of 0.13.

Haleon (NYSE:HLN) last issued its earnings results on Saturday, February 14th. The company reported $6.32 earnings per share for the quarter. The business had revenue of $3.65 billion during the quarter. Equities analysts expect that Haleon PLC Sponsored ADR will post 0.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on HLN shares. Argus raised Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Rothschild & Co Redburn cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Haleon has a consensus rating of “Moderate Buy”.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.